Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Checkpoint Therapeutics Inc Market Cap
Based on ratings from 1 stock analysts, the Checkpoint Therapeutics Inc stock price is expected to increase by 885% in 12 months. This is calculated by using the average 12-month stock price forecast for Checkpoint Therapeutics Inc. The lowest target is $4 and the highest is $34. Please note analyst price targets are not guaranteed and could be missed completely.
About 1 Wall Street analysts have assignedCKPT 1 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Checkpoint Therapeutics Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CKPT. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CKPT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Joseph Pantginis HC Wainwright & Co. | Buy | $20 | Maintains | Aug 12, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $34 | Reiterates | Jul 16, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $34 | Reiterates | Jun 24, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $34 | Reiterates | May 16, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $34 | Reiterates | Mar 22, 2024 |
| Mayank Mamtani B. Riley Securities | Buy | $4 | Maintains | Dec 20, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $34 | Reiterates | Dec 19, 2023 |
| Thomas Flaten Lake Street | Buy | $14 | Maintains | Aug 16, 2023 |
| Jeffrey Cohen Ladenburg Thalmann | Buy | $47 | Maintains | Aug 15, 2023 |
| Jennifer Kim Cantor Fitzgerald | Overweight | $14 | Maintains | Aug 15, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $34 | Reiterates | Aug 4, 2023 |
Cantor Fitzgerald | Overweight | Maintains | Jun 20, 2023 | |
Lake Street | Buy | Maintains | May 30, 2023 | |
| Jeffrey Cohen Ladenburg Thalmann | Buy | $65 | Maintains | May 17, 2023 |
| Jennifer Kim Cantor Fitzgerald | Overweight | $19 | Maintains | May 16, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $34 | Maintains | Apr 28, 2023 |
| Thomas Flaten Lake Street | Buy | $22 | Maintains | Apr 4, 2023 |
Ladenburg Thalmann | Buy | $69 | Maintains | Apr 3, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $76 | Reiterates | Mar 2, 2023 |
Cantor Fitzgerald | Overweight | Maintains | Jan 4, 2023 |
When did it IPO
N/A
Staff Count
23
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. James F. Oliviero III, C.F.A.
Market Cap
$101.3M
In 2023, CKPT generated $103,000 in revenue, which was a decrease of -46.35% from the previous year. This can be seen as a signal that CKPT's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 27 Aug 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Checkpoint Therapeutics' Cosibelimab, an anti-PD-L1 antibody, shows promise for treating cSCC, with potential FDA approval by December 2024, making CKPT a speculative "buy." Cosibelimab's dual mechanism of action, engaging both T cells and NK cells, offers a competitive edge over other PD-L1 inhibitors, enhancing its efficacy. Despite CKPT's low cash reserves and regulatory risks, the potential market for Cosibelimab in cSCC treatment is estimated at over $1 billion in the US.
Fri, 16 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Checkpoint Therapeutics (CKPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Mon, 12 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2024, and recent corporate updates.
Thu, 25 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Checkpoint's resubmission of its Biologics License Application (“BLA”) for cosibelimab, its anti-programmed death ligand-1 (“PD-L1”) antibody, as a potential new treatment for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”) who are not candidates for curative surgery or curative radiation.
Mon, 15 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoint Therapeutics ("Checkpoint") (Nasdaq: CKPT) have announced a collaboration to explore the combined therapeutic potential of cosibelimab, Checkpoint's anti-PD-L1 antibody with dual mechanism of action, with GC Cell's Immuncell-LC, an innovative autologous Cytokine Induced Killer (“CIK”) T cell therapy composed of cytotoxic T lymphocytes and natural killer T cells.
Tue, 02 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has completed the resubmission of its Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for cosibelimab, its anti-programmed death ligand-1 (“PD-L1”) antibody, as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”) who are not candidates for curative surgery or curative radiation.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
